martes, 29 de noviembre de 2011
Bayer YAZ to follow Merck´s Vioxx?
Now fast forward to 2011. We have been locked in a battle with Bayer, over its YAZ, Yasmin and Ocella oral contraceptive pills. Similar allegations are being levelled against Bayer for its over marketing and promotion for the all types of pre-menstrual tension, when it was only approved for the worst type, pre-menstrual dysphoric disorder.
It was never approved for that by the FDA. Bayer had to spend $20 million in a fine for false and misleading advertising and re-do its ads. Now many plaintiffs are alleging and medical studies are revealing that Bayer's drugs have a higher risk profile for venous thromboembolism. Bayer hotly contestes this allegation. The first of many bellwether trials are scheduled to take place in January 2012. (Ver)
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario